Yamagami S, Tsuru T, Isobe M, Obata H, Suzuki J
Department of Ophthalmology, Jichi Medical School, Tochigi, Japan.
Graefes Arch Clin Exp Ophthalmol. 1996 Jun;234(6):382-7. doi: 10.1007/BF00190715.
It has been reported that adhesion molecules play an important role in immunological rejection after organ transplantation. In the present study, we examined the role of ICAM-1/ LFA-1 adhesion molecules in corneal allograft rejection and evaluated the immunological specificity of monoclonal antibodies (mAbs) in preventing allograft rejection in mice.
The allografted mice were intraperitoneally injected with 100 micrograms/day of the following mAbs: a control mAb, anti-ICAM-1 mAb, anti-LFA-1 mAb, or a mixture of anti-ICAM-1 and anti-LFA-1 mAbs from 1 day before to 7 days after surgery. The expression of ICAM-1 and LFA-1 molecules in the grafted cornea was studied immunohistochemically. The corneas from a syngeneic donor or a third-party strain were transplanted 4 weeks after the initial keratoplasty onto the mice treated with both anti-ICAM-1 and anti-LFA-1 mAbs.
The allografts treated with anti-LFA-1 mAb alone or both anti-ICAM-1 and anti-LFA-1 mAbs remained transparent for more than 2 weeks, and the survival rate at 8 weeks was 40% in both groups. ICAM-1 was expressed on the mononuclear cells, keratocytes and endothelial cells in the allografts without treatment. The second corneal grafts syngeneic to the initial donor remained transparent at 2 weeks, whereas those from the third party were rejected.
ICAM-1 and LFA-1 adhesion molecules play a crucial role in the pathophysiology of corneal transplant rejection. The immunosuppressive effects of anti-ICAM-1 and anti-LFA-1 mAbs are highly allospecific. The administration of mAbs to the adhesion molecules represents a new means of suppressing allograft rejection after penetrating keratoplasty.
据报道,黏附分子在器官移植后的免疫排斥反应中起重要作用。在本研究中,我们检测了细胞间黏附分子-1(ICAM-1)/淋巴细胞功能相关抗原-1(LFA-1)黏附分子在角膜移植排斥反应中的作用,并评估了单克隆抗体(mAb)预防小鼠移植排斥反应的免疫特异性。
从手术前1天至手术后7天,给同种异体移植小鼠腹腔注射以下mAb,剂量为100微克/天:对照mAb、抗ICAM-1 mAb、抗LFA-1 mAb或抗ICAM-1和抗LFA-1 mAb的混合物。采用免疫组织化学方法研究移植角膜中ICAM-1和LFA-1分子的表达。在初次角膜移植术后4周,将同基因供体或第三方品系的角膜移植到用抗ICAM-1和抗LFA-1 mAb治疗的小鼠身上。
单独用抗LFA-1 mAb或抗ICAM-1和抗LFA-1 mAb联合治疗的同种异体移植物在2周以上保持透明,两组8周时的存活率均为40%。未经治疗的同种异体移植物中的单核细胞、角膜细胞和内皮细胞表达ICAM-1。与初次供体同基因的第二次角膜移植物在2周时保持透明,而来自第三方的移植物被排斥。
ICAM-1和LFA-1黏附分子在角膜移植排斥反应的病理生理过程中起关键作用。抗ICAM-1和抗LFA-1 mAb的免疫抑制作用具有高度的同种特异性。向黏附分子注射mAb是穿透性角膜移植术后抑制同种异体移植排斥反应的一种新方法。